107 related articles for article (PubMed ID: 21565951)
1. Patient weight-based acquisition protocols to optimize (18)F-FDG PET/CT image quality.
Nagaki A; Onoguchi M; Matsutomo N
J Nucl Med Technol; 2011 Jun; 39(2):72-6. PubMed ID: 21565951
[TBL] [Abstract][Full Text] [Related]
2. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.
Halpern BS; Dahlbom M; Auerbach MA; Schiepers C; Fueger BJ; Weber WA; Silverman DH; Ratib O; Czernin J
J Nucl Med; 2005 Apr; 46(4):603-7. PubMed ID: 15809482
[TBL] [Abstract][Full Text] [Related]
3. Investigation of 18F-FDG 3D mode PET image quality versus acquisition time.
Brown C; Dempsey MF; Gillen G; Elliott AT
Nucl Med Commun; 2010 Mar; 31(3):254-9. PubMed ID: 20032801
[TBL] [Abstract][Full Text] [Related]
4. Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard.
Brambilla M; Secco C; Dominietto M; Matheoud R; Sacchetti G; Inglese E
J Nucl Med; 2005 Dec; 46(12):2083-91. PubMed ID: 16330574
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
6. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
Hallett WA; Maguire RP; McCarthy TJ; Schmidt ME; Young H
IDrugs; 2007 Nov; 10(11):791-6. PubMed ID: 17968761
[TBL] [Abstract][Full Text] [Related]
7. Weight-based, low-dose pediatric whole-body PET/CT protocols.
Alessio AM; Kinahan PE; Manchanda V; Ghioni V; Aldape L; Parisi MT
J Nucl Med; 2009 Oct; 50(10):1570-7. PubMed ID: 19793734
[TBL] [Abstract][Full Text] [Related]
8. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
9. Two-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study.
Bettinardi V; Mancosu P; Danna M; Giovacchini G; Landoni C; Picchio M; Gilardi MC; Savi A; Castiglioni I; Lecchi M; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):214-23. PubMed ID: 17464266
[TBL] [Abstract][Full Text] [Related]
10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
11. Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system.
Okubo M; Nishimura Y; Nakamatsu K; Okumura M; Shibata T; Kanamori S; Hanaoka K; Hosono M
Ann Nucl Med; 2008 Aug; 22(7):579-86. PubMed ID: 18756360
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET/CT in the diagnosis of fever of unknown origin.
Balink H; Collins J; Bruyn GA; Gemmel F
Clin Nucl Med; 2009 Dec; 34(12):862-8. PubMed ID: 20139818
[TBL] [Abstract][Full Text] [Related]
13. When to image carotid plaque inflammation with FDG PET/CT.
Graebe M; Borgwardt L; Højgaard L; Sillesen H; Kjaer A
Nucl Med Commun; 2010 Sep; 31(9):773-9. PubMed ID: 20543757
[TBL] [Abstract][Full Text] [Related]
14. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
Strobel K; Rüdy M; Treyer V; Veit-Haibach P; Burger C; Hany TF
Nucl Med Commun; 2007 Jul; 28(7):555-9. PubMed ID: 17538397
[TBL] [Abstract][Full Text] [Related]
15. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
16. Could different hydration protocols affect the quality of 18F-FDG PET/CT images?
Ceriani L; Suriano S; Ruberto T; Giovanella L
J Nucl Med Technol; 2011 Jun; 39(2):77-82. PubMed ID: 21565956
[TBL] [Abstract][Full Text] [Related]
17. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers.
Breen SL; Publicover J; De Silva S; Pond G; Brock K; O'Sullivan B; Cummings B; Dawson L; Keller A; Kim J; Ringash J; Yu E; Hendler A; Waldron J
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):763-70. PubMed ID: 17379435
[TBL] [Abstract][Full Text] [Related]
18. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
19. The determination of patient dose from (18)F-FDG PET/CT examination.
Khamwan K; Krisanachinda A; Pasawang P
Radiat Prot Dosimetry; 2010 Sep; 141(1):50-5. PubMed ID: 20400773
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
